OBJECTIVE:

To assess the impact of oral cannabidiol ( CBD) administration in addition to standard antiepileptic remedy on seizure frequency in dogs with idiopathic epilepsy.

Design and style:

Randomized blinded controlled clinical trial.

ANIMALS:

26 client-owned dogs with intractable idiopathic epilepsy.

PROCEDURES:

Dogs have been randomly assigned to a CBD (n = 12) or placebo (14) group. The CBD group received CBD-infused oil (two.five mg/kg [1.1 mg/lb], PO) twice everyday for 12 weeks in addition to current antiepileptic remedies, and the placebo group received noninfused oil beneath the very same circumstances. Seizure activity, adverse effects, and plasma CBD concentrations have been compared among groups.

Outcomes:

two dogs in the CBD group created ataxia and have been withdrawn from the study. Just after other exclusions, 9 dogs in the CBD group and 7 in the placebo group have been incorporated in the evaluation. Dogs in the CBD group had a considerable (median alter, 33%) reduction in seizure frequency, compared with the placebo group. On the other hand, the proportion of dogs deemed responders to remedy (≥ 50% lower in seizure activity) was comparable among groups. Plasma CBD concentrations have been correlated with reduction in seizure frequency. Dogs in the CBD group had a considerable boost in serum alkaline phosphatase activity. No adverse behavioral effects have been reported by owners.

CONCLUSIONS AND CLINICAL RELEVANCE:

While a considerable reduction in seizure frequency was accomplished for dogs in the CBD group, the proportion of responders was comparable among groups. Provided the correlation among plasma CBD concentration and seizure frequency, further investigation is warranted to establish no matter whether a greater dosage of CBD would be productive in minimizing seizure activity by ≥ 50%.